Axaron's functional regeneration

In stroke, brain damage is enhanced by the formation of oxygen radicals that send neurons in a vast area around the primary site into apoptosis. Among the companies trying to develop neuroprotectants to limit this damage, Axaron Bioscience AG claims that its AX200 has neuroregenerative properties, as well, supporting the formation of new neurons.

AX200, which entered a German Phase II trial in September, is an undisclosed marketed drug against a receptor target whose role in stroke was previously unknown. Axaron (Heidelberg, Germany) is evaluating it in stroke along with AX201, a related compound with a different efficacy profile, which is in late preclinical studies. Results of the AX200 trial are expected in mid-2005...